Lacklustre debut for RaQualia in Japan
This article was originally published in Scrip
Shares in the Japanese drug development venture RaQualia Pharma began trading below their offer price on 20 July, reflecting apparent investor caution over a new business plan released by the company the same day.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.